Richard Siegel is an Endocrinology/Metabolic physician affiliated with Tufts Medical Center. OpenAlex indexes 67 publications with 1,444 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
750 Washington St
Nemc Box 836
Boston, MA 021111526
Telephone
617-636-5000Registry record last updated 8 Jul 2007.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Azurity Pharmaceuticals, Inc.Program year20252 payments
- CeQur CorporationProgram year20251 payment
- ROCHE DIABETES CARE, INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
70.8%GLP-1 receptor agonist25.6%Trulicity43%Ozempic38%Mounjaro15%Rybelsus4%Part D<11 patientsInsulin Analog19.7%Humalog Kwikpen U-10018%Lantus Solostar13%Humalog11%Tresiba Flextouch U-10010%Tresiba Flextouch U-2009%Novolog9%Basaglar Kwikpen U-1008%Toujeo Solostar8%Novolog Flexpen6%Fiasp Flextouch5%Admelog Solostar4%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
13.7%l-Thyroxine10.2%Levothyroxine Sodium79%Synthroid21%Part D<11 patientsThyroid Hormone Synthesis Inhibitor3.5%Methimazole100%Part D≥19 patientsCardiovascular
12.4%Statin6.9%Atorvastatin Calcium50%Rosuvastatin Calcium40%Simvastatin10%Part D<11 patientsCholesterol absorption inhibitor3.2%Ezetimibe100%Part D≥12 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SAT-261 Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia
Journal of the Endocrine Society
2025 - MON-045 A Case of Familial Partial Lipodystrophy Type 2 With Isolated Hepatic Steatosis
Journal of the Endocrine Society
2024 - SUN-677 The Warburg Effect: A Case of Persistent Hypoglycemia and Lactic Acidosis
Journal of the Endocrine Society
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Levey, MD
Tufts Medical Center
Mark Sarnak, MD
Tufts Medical Center
James Udelson, MD
Tufts Medical Center
Nicholas Hill, MD
Tufts Medical Center
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”